GLP-1/GIP (tirzepatide) — The Dual Incretin Agonist
Tirzepatide is a dual GIP and GLP-1 receptor agonist that significantly improves glycemic control and induces substantial weight loss. Its relevance to longevity stems from its profound ability to reverse metabolic syndrome, reduce visceral adiposity, and improve cardiometabolic biomarkers, which are key drivers of age-related chronic diseases.
Mechanism of Action
Tirzepatide is a synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By binding to these receptors, it enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying. The synergistic activation of GIP and GLP-1 pathways leads to significant reductions in appetite and caloric intake, while also improving insulin sensitivity and lipid metabolism. Downstream effects include the modulation of metabolic pathways that reduce visceral adiposity and systemic inflammation, contributing to improved cardiometabolic health.
Human Trial Evidence
Tirzepatide has demonstrated profound efficacy in human trials for weight loss and glycemic control. In the SURMOUNT-1 trial (2022, NEJM), participants without diabetes achieved up to 20.9% body weight reduction over 72 weeks. The SURPASS-2 trial (2021, NEJM) showed superior HbA1c reductions and weight loss compared to semaglutide in patients with type 2 diabetes. Long-term human longevity data is not yet available, but improvements in cardiometabolic risk factors are well-documented.
Dosing Protocol
2.5 mg to 15 mg administered subcutaneously once weekly. The starting dose is 2.5 mg once weekly for 4 weeks, followed by an increase to 5 mg once weekly. Dose escalation may continue in 2.5 mg increments every 4 weeks up to a maximum of 15 mg once weekly based on tolerability and clinical response. Prescription required.
Safety & Contraindications
Common adverse effects are primarily gastrointestinal, including nausea, diarrhea, vomiting, and constipation, which are typically dose-dependent and transient. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Caution is advised in patients with a history of pancreatitis or severe gastrointestinal disease. Prescription required.